EA201071421A1 - Анти-flt3 антитела - Google Patents
Анти-flt3 антителаInfo
- Publication number
- EA201071421A1 EA201071421A1 EA201071421A EA201071421A EA201071421A1 EA 201071421 A1 EA201071421 A1 EA 201071421A1 EA 201071421 A EA201071421 A EA 201071421A EA 201071421 A EA201071421 A EA 201071421A EA 201071421 A1 EA201071421 A1 EA 201071421A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- present
- flt3 antibodies
- flt3
- administering
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Согласно настоящему изобретению предложены полностью человеческие антитела, которые специфично связываются с FLT3 человека в пределах внеклеточных доменов 4 или 5 с высокой аффинностью. Согласно настоящему изобретению также предложены способы лечения лейкоза путем введения эффективного количества указанного антитела отдельно или в комбинации с противораковым средством или лечением, включая метотрексат.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13039408P | 2008-05-30 | 2008-05-30 | |
US13039508P | 2008-05-30 | 2008-05-30 | |
US13053908P | 2008-05-30 | 2008-05-30 | |
PCT/US2009/045365 WO2009155015A1 (en) | 2008-05-30 | 2009-05-28 | Anti-flt3 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201071421A1 true EA201071421A1 (ru) | 2011-08-30 |
Family
ID=41092183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201071421A EA201071421A1 (ru) | 2008-05-30 | 2009-05-28 | Анти-flt3 антитела |
Country Status (18)
Country | Link |
---|---|
US (3) | US20110091470A1 (ru) |
EP (1) | EP2300500A1 (ru) |
JP (1) | JP2011521647A (ru) |
KR (1) | KR20110004455A (ru) |
CN (1) | CN102046659A (ru) |
AR (1) | AR071891A1 (ru) |
AU (1) | AU2009260517B2 (ru) |
BR (1) | BRPI0912173A2 (ru) |
CA (1) | CA2726522A1 (ru) |
CL (1) | CL2009001277A1 (ru) |
EA (1) | EA201071421A1 (ru) |
IL (1) | IL209142A0 (ru) |
MX (1) | MX2010013144A (ru) |
NZ (1) | NZ588791A (ru) |
PE (1) | PE20091963A1 (ru) |
TW (1) | TWI374032B (ru) |
WO (1) | WO2009155015A1 (ru) |
ZA (1) | ZA201008024B (ru) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
HUE045270T2 (hu) | 2010-01-05 | 2019-12-30 | Inst Nat Sante Rech Med | FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére |
US20130156764A1 (en) * | 2010-03-12 | 2013-06-20 | The Johns Hopkins University | Neutralization of flt3 ligand as a leukemia therapy |
EA201790757A1 (ru) * | 2011-09-22 | 2017-07-31 | Эмджен Инк. | Связывающие антиген cd27l белки |
US20150064203A1 (en) * | 2012-03-08 | 2015-03-05 | Japan Science And Technology Agency | Anticancer agent |
EP3119423B1 (en) | 2014-03-15 | 2022-12-14 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
WO2016145099A1 (en) * | 2015-03-09 | 2016-09-15 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to flt3 proteins |
US20180298068A1 (en) | 2015-04-23 | 2018-10-18 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
KR20180053744A (ko) * | 2015-09-23 | 2018-05-23 | 사이토이뮨 테라퓨틱스 엘엘씨 | 면역 요법을 위한 flt3 유도된 car 세포 |
CN108603200B (zh) | 2015-11-23 | 2022-08-19 | 诺华股份有限公司 | 优化的慢病毒转移载体及其用途 |
MX2018008106A (es) | 2015-12-30 | 2019-03-14 | Novartis Ag | Terapias con celulas inmunoefectoras de una eficacia mejorada. |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
EP3464366A1 (en) * | 2016-05-27 | 2019-04-10 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Flt3-specific chimeric antigen receptors and methods using same |
KR20230066647A (ko) | 2016-06-17 | 2023-05-16 | 마젠타 테라퓨틱스 인코포레이티드 | Cd117+ 세포의 고갈을 위한 조성물 및 방법 |
WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
CA3045902A1 (en) | 2016-12-21 | 2018-06-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
CN110461876B (zh) | 2017-01-20 | 2024-05-17 | 海德堡医药研究有限责任公司 | 用于耗尽cd137+细胞的组合物和方法 |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
JP2020506700A (ja) | 2017-01-31 | 2020-03-05 | ノバルティス アーゲー | 多重特異性を有するキメラt細胞受容体タンパク質を用いた癌の治療 |
EP3589647A1 (en) | 2017-02-28 | 2020-01-08 | Novartis AG | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
AU2018269678A1 (en) | 2017-05-17 | 2019-12-12 | Biodol Therapeutics | FLT3 inhibitors for improving pain treatments by opioids |
TWI757499B (zh) * | 2017-06-02 | 2022-03-11 | 美商輝瑞大藥廠 | 對flt3具特異性之抗體及其用途 |
US20230181634A1 (en) * | 2017-06-02 | 2023-06-15 | Pfizer Inc. | Chimeric antigen receptors targeting flt3 |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
SG11202000632QA (en) * | 2017-07-31 | 2020-02-27 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and flt3 |
EP3700926A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
EP3700933A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
WO2019089798A1 (en) | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
WO2020128638A1 (en) * | 2018-12-18 | 2020-06-25 | Northern Biologics Inc. | Flt3 agonist antibodies and uses thereof |
JP2022514315A (ja) | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | 3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体を含む投与計画及び薬剤組み合わせ |
JP7488826B2 (ja) | 2019-02-15 | 2024-05-22 | ノバルティス アーゲー | 置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用 |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020210719A1 (en) * | 2019-04-10 | 2020-10-15 | Elevatebio Management, Inc. | Flt3-specific chimeric antigen receptors and methods of using the same |
SG11202111130SA (en) * | 2019-04-30 | 2021-11-29 | Senti Biosciences Inc | Chimeric receptors and methods of use thereof |
TW202112812A (zh) * | 2019-05-24 | 2021-04-01 | 香港商安立璽榮生醫(香港)有限公司 | Csf1r抗體、il10融合蛋白及其用途 |
AU2020366000A1 (en) * | 2019-10-15 | 2022-05-12 | Dragonfly Therapeutics, Inc. | Antibodies targeting FLT3 and use thereof |
US20230056470A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
AU2021255884A1 (en) | 2020-04-14 | 2022-11-17 | Les Laboratoires Servier | Anti-FLT3 antibodies and compositions |
EP4135851A1 (en) | 2020-04-17 | 2023-02-22 | City of Hope | Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignancies |
EP4142749A1 (en) | 2020-04-30 | 2023-03-08 | The Regents of the University of Colorado, A Body Corporate | Multispecific anti-flt3 chimeric antigen receptors |
JP2023529211A (ja) | 2020-06-11 | 2023-07-07 | ノバルティス アーゲー | Zbtb32阻害剤及びその使用 |
CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
CN111808821B (zh) * | 2020-06-24 | 2022-06-14 | 南方医科大学珠江医院 | Flt3-nkg2d双靶点car-t的构建与制备 |
CN116134027A (zh) | 2020-08-03 | 2023-05-16 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
IL302700A (en) | 2020-11-13 | 2023-07-01 | Novartis Ag | Combined treatments with cells expressing chimeric antigens (vehicle) |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125468A1 (es) | 2021-04-27 | 2023-07-19 | Novartis Ag | Sistema de producción de vectores virales |
AU2022330106A1 (en) * | 2021-08-16 | 2024-03-21 | Hemogenyx Pharmaceuticals Llc | Anti-flt3 antibodies, cars, car t cells and methods of use |
WO2023105087A1 (en) * | 2021-12-10 | 2023-06-15 | Tubulis Gmbh | Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3869584D1 (de) | 1987-04-03 | 1992-04-30 | Hermann Hofmann | Verfahren zum kompostieren von organischen stoffen und vorrichtung zur durchfuehrung dieses verfahrens. |
AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5367057A (en) * | 1991-04-02 | 1994-11-22 | The Trustees Of Princeton University | Tyrosine kinase receptor flk-2 and fragments thereof |
US5185438A (en) | 1991-04-02 | 1993-02-09 | The Trustees Of Princeton University | Nucleic acids encoding hencatoporetic stem cell receptor flk-2 |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
US7537932B1 (en) * | 1993-05-19 | 2009-05-26 | Schering Corporation | Antibodies that bind purified mammalian FLT3 ligands |
US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
JPH09502352A (ja) | 1993-09-08 | 1997-03-11 | イムクローン システムズ インコーポレイテッド | Flk−2レセプターを認識するモノクローナル抗体および原始造血幹細胞集団の単離 |
US5635388A (en) * | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
DE19608769C1 (de) * | 1996-03-07 | 1997-04-10 | Univ Eberhard Karls | Antikörper BV10A4H2 |
US6084060A (en) | 1996-12-09 | 2000-07-04 | Imclone Systems Incorporated | Composition and method for preserving progenitor cells |
DE19727814C1 (de) * | 1997-06-30 | 1998-10-01 | Univ Eberhard Karls | Anitkörper 4G8B4B12 |
JP2002515511A (ja) | 1998-05-15 | 2002-05-28 | イムクローン システムズ インコーポレイティド | 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療 |
US6999122B1 (en) * | 1999-07-22 | 2006-02-14 | Minolta Co., Ltd. | Solid-state logarithmic image sensing device |
AU2002329540A1 (en) | 2001-06-20 | 2003-01-02 | Morphosys Ag | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
WO2005094823A1 (ja) | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | Flt-3阻害剤 |
US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
WO2008153926A2 (en) | 2007-06-05 | 2008-12-18 | Yale University | Inhibitors of receptor tyrosine kinases and methods of use thereof |
AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
-
2009
- 2009-05-22 AR ARP090101855A patent/AR071891A1/es not_active Application Discontinuation
- 2009-05-25 CL CL2009001277A patent/CL2009001277A1/es unknown
- 2009-05-25 PE PE2009000733A patent/PE20091963A1/es not_active Application Discontinuation
- 2009-05-28 WO PCT/US2009/045365 patent/WO2009155015A1/en active Application Filing
- 2009-05-28 MX MX2010013144A patent/MX2010013144A/es active IP Right Grant
- 2009-05-28 BR BRPI0912173A patent/BRPI0912173A2/pt not_active IP Right Cessation
- 2009-05-28 JP JP2011511791A patent/JP2011521647A/ja not_active Withdrawn
- 2009-05-28 EA EA201071421A patent/EA201071421A1/ru unknown
- 2009-05-28 US US12/994,956 patent/US20110091470A1/en not_active Abandoned
- 2009-05-28 CN CN2009801189357A patent/CN102046659A/zh active Pending
- 2009-05-28 US US12/473,295 patent/US20090297529A1/en not_active Abandoned
- 2009-05-28 NZ NZ588791A patent/NZ588791A/en not_active IP Right Cessation
- 2009-05-28 AU AU2009260517A patent/AU2009260517B2/en not_active Expired - Fee Related
- 2009-05-28 CA CA2726522A patent/CA2726522A1/en not_active Abandoned
- 2009-05-28 EP EP09767327A patent/EP2300500A1/en not_active Ceased
- 2009-05-28 KR KR1020107026790A patent/KR20110004455A/ko not_active Application Discontinuation
- 2009-06-01 TW TW098118092A patent/TWI374032B/zh not_active IP Right Cessation
-
2010
- 2010-09-27 US US12/890,793 patent/US8071099B2/en not_active Expired - Fee Related
- 2010-11-04 IL IL209142A patent/IL209142A0/en unknown
- 2010-11-09 ZA ZA2010/08024A patent/ZA201008024B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2009260517B2 (en) | 2012-12-06 |
US8071099B2 (en) | 2011-12-06 |
US20090297529A1 (en) | 2009-12-03 |
WO2009155015A1 (en) | 2009-12-23 |
AU2009260517A1 (en) | 2009-12-23 |
AR071891A1 (es) | 2010-07-21 |
IL209142A0 (en) | 2011-01-31 |
KR20110004455A (ko) | 2011-01-13 |
ZA201008024B (en) | 2012-04-25 |
PE20091963A1 (es) | 2010-01-15 |
US20110091470A1 (en) | 2011-04-21 |
CA2726522A1 (en) | 2009-12-23 |
JP2011521647A (ja) | 2011-07-28 |
MX2010013144A (es) | 2010-12-21 |
TW201010722A (en) | 2010-03-16 |
EP2300500A1 (en) | 2011-03-30 |
BRPI0912173A2 (pt) | 2016-07-26 |
CN102046659A (zh) | 2011-05-04 |
US20110008355A1 (en) | 2011-01-13 |
NZ588791A (en) | 2012-05-25 |
TWI374032B (en) | 2012-10-11 |
CL2009001277A1 (es) | 2010-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201071421A1 (ru) | Анти-flt3 антитела | |
PH12019501393A1 (en) | Afucosylated anti-fgfr2iiib antibodies | |
EA201490717A1 (ru) | АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ | |
CY1118668T1 (el) | Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
EA201500393A1 (ru) | Ингибиторы тирозинкиназы брутона | |
EA201100239A1 (ru) | Композиции, одновалетные в отношении связывания cd28, и способы их применения | |
MX2018001532A (es) | Anticuerpos anti-angptl8 y usos de estos. | |
UA112434C2 (uk) | Антигензв'язувальний білок, який специфічно зв'язується з всма | |
BRPI0607728A2 (pt) | complexo de lipoproteìna carregado reconstituìdo, composição farmacêutica, e, uso de um complexo de lipoproteìna carregado | |
PH12015500576A1 (en) | Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
PL1830881T3 (pl) | Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie | |
PE20090227A1 (es) | Composiciones farmaceuticas que comprenden agentes anti-beta-klotho | |
MY165273A (en) | Anti-cd48 antibodies and uses thereof | |
EA201391507A1 (ru) | АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ | |
ATE534752T1 (de) | Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll) | |
EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
EA201300978A1 (ru) | Антитела к сеа | |
ME01532B (me) | Jedinjenja | |
SG158112A1 (en) | Hepatocyte growth factor (hgf) binding proteins | |
EA201390813A1 (ru) | Антитела и их применение | |
MX2011006725A (es) | Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20. | |
EA201201623A1 (ru) | Лечение диабета 2 типа | |
CR11126A (es) | Inhibicion de metastasis de tumor por anticuerpos anti neuropilina 2 |